Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
P74 Ventures is a Boston-based venture capital firm founded in 2022, focusing on the intersection of pharmaceuticals and technology. The firm aims to expand access to healthcare and improve global health and wellness through strategic investments in technology companies that drive innovation within the life sciences industry. P74 Ventures is particularly focused on the business and operations of pharma, rather than biotech drug discovery.
The firm operates globally, with a strong emphasis on North America, and targets early-stage investments across various funding stages, including pre-seed, seed, Series A, Series B, and growth equity. P74 Ventures is committed to enhancing the operations of pharmaceutical companies through innovative technologies that address significant industry challenges.
As of now, P74 Ventures has made one notable investment in TransVoyant, an intelligent supply-chain execution platform. The firm is positioned to leverage its deep industry experience and connections within the pharmaceutical sector to facilitate partnerships and collaborations that enhance business growth.
P74 Ventures invests in early-stage pharma-tech and platform-technology companies that can transform the operations of pharmaceutical businesses. Their investment strategy is centered around initiatives that enhance healthcare access and improve global health outcomes. The firm specifically targets companies that address pharma's business bottlenecks, including drug cost, patient access, and supply-chain performance.
Investment stages include pre-seed, seed, Series A, Series B, and growth equity, allowing P74 Ventures to engage with startups at various points in their development. The firm seeks to partner with companies where at least one pharmaceutical company can be a founding partner or collaborator, ensuring a strong alignment with industry needs. Geographic focus is primarily on North America, but the firm is open to global opportunities.
P74 Ventures has made a strategic investment in the following company:
Jeremy Sohn - Managing Partner / Founder. Jeremy has a background as a venture investor and entrepreneur, with significant experience in the life sciences sector. He previously served as VP, Global Head of Digital BD&L, Partnerships & Innovation at Novartis, overseeing pharma-tech and digital health ventures. He was also a Managing Director at MPM Capital and co-founder of Wasabi Systems.
Ronny Hashmonay, MD - Partner / Co-founder. Ronny co-created P74 Ventures with Jeremy Sohn after working with him at Novartis. His specific current role and background details are not disclosed in available sources, but he brings valuable expertise in the pharma-tech space.
To pitch P74 Ventures, founders should visit their website at p74ventures.com. While specific details regarding the pitch process are not publicly disclosed, it is advisable to include a clear articulation of how the startup's technology addresses challenges within the pharmaceutical sector. Founders should also highlight any existing partnerships or collaborations with pharmaceutical companies, as this aligns with P74's investment thesis.
In December 2022, P74 Ventures co-led a strategic growth equity financing round for TransVoyant, an intelligent supply-chain execution platform, alongside Merck Global Health Innovation Fund. This investment aims to enhance supply-chain performance within the life sciences sector.
What are P74 Ventures' investment criteria?
P74 Ventures focuses on early-stage pharma-tech and platform-technology companies that can enhance the operations of pharmaceutical businesses. They look for initiatives that improve healthcare access and global health outcomes, particularly those addressing business bottlenecks in the pharma sector.
How can I pitch to P74 Ventures?
Founders interested in pitching to P74 Ventures can visit their website at p74ventures.com for more information. Specific details regarding the pitch process are not publicly disclosed.
What makes P74 Ventures different from other VC firms?
P74 Ventures distinguishes itself by focusing specifically on the intersection of pharmaceuticals and technology. Their expertise lies in enhancing the business operations of pharma companies rather than investing in biotech drug discovery.
What is the geographic scope of P74 Ventures?
The firm primarily focuses on North America but is open to global investment opportunities within the pharma-tech sector.
What is the typical check size for investments?
Specific check sizes are not disclosed, but P74 Ventures invests across various stages, including pre-seed, seed, Series A, Series B, and growth equity.
What kind of support do portfolio companies receive?
P74 Ventures provides strategic support to its portfolio companies by leveraging deep industry experience and connections within the pharmaceutical sector, facilitating partnerships and collaborations that enhance business growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.